Akira Shibuya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Akira Shibuya has a total of 290 co-authors. Here are the top co-authors by number of shared publications:
- Kazuko Shibuya
University of Tsukuba
32 shared publications Satoko Tahara-Hanaoka
Univ Tsukuba, Fac Med, Dept Immunol, Tsukuba, Ibaraki, Japan
19 shared publicationsKazuko Shibuya
Department of Immunology, Institute of Medicine, University of Tsukuba; Tsukuba, Ibaraki, Japan
15 shared publicationsShin-Ichiro Honda
Department of Immunology, Life Science Center of Tsukuba Advanced Research Alliance (TARA) and Faculty of Medicine, University of Tsukuba, Ten-nodai, Tsukuba, Ibaraki, Japan
13 shared publicationsTsukasa Nabekura
Life Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba
13 shared publications- Chigusa Nakahashi-Oda
Department of Immunology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
10 shared publications
Latest Publications
- Open Access
CD300a Blockade attenuates renal fibrosis by enhancing macrophage efferocytosis and neutrophil MMP9 production
Renal fibrosis represents an irreversible endpoint of chronic kidney disease. Although macrophage efferocytosis regulates the response to acute renal injury, the mechanisms by which early efferocytosis confers long-term protection against chronic fibrosis remain elusive. Here, we show that phagocyte-specific deletion of the inhibitory receptor CD300a ( Cd300a fl/fl Lyz2- Cre) mitigates obstructive renal injury and subsequent fibrosis. CD300a deficiency enhanced efferocytosis by tissue-resident macrophages during the early phase of injury, thereby suppressing the release of damage-associated molecular patterns (DAMPs) and TGF-β expression. This early attenuation of the inflammatory microenvironment altered the composition of recruited neutrophils, shifting them from profibrotic SiglecF+ toward non-profibrotic SiglecF− subsets. Furthermore, loss of CD300a cell-autonomously primed neutrophils for enhanced matrix metalloproteinase-9 (MMP9) production upon injury, whereas neutrophil depletion abolished the protective effect of CD300a deficiency. Importantly, administration of a neutralizing anti-CD300a antibody to wild-type mice recapitulated these protective effects, promoting the shift toward SiglecF− neutrophils and significantly attenuating renal fibrosis. Together, our findings identify CD300a as a regulator of early macrophage efferocytosis and neutrophil-derived MMP9 production, and establish pharmacological CD300a blockade as a potential therapeutic strategy for progressive renal fibrosis.
Open AccessCD300a Blockade attenuates renal fibrosis by enhancing macrophage efferocytosis and neutrophil MMP9 production
Renal fibrosis represents an irreversible endpoint of chronic kidney disease. Although macrophage efferocytosis regulates the response to acute renal injury, the mechanisms by which early efferocytosis confers long-term protection against chronic fibrosis remain elusive. Here, we show that phagocyte-specific deletion of the inhibitory receptor CD300a ( Cd300a fl/fl Lyz2- Cre) mitigates obstructive renal injury and subsequent fibrosis. CD300a deficiency enhanced efferocytosis by tissue-resident macrophages during the early phase of injury, thereby suppressing the release of damage-associated molecular patterns (DAMPs) and TGF-β expression. This early attenuation of the inflammatory microenvironment altered the composition of recruited neutrophils, shifting them from profibrotic SiglecF+ toward non-profibrotic SiglecF− subsets. Furthermore, loss of CD300a cell-autonomously primed neutrophils for enhanced matrix metalloproteinase-9 (MMP9) production upon injury, whereas neutrophil depletion abolished the protective effect of CD300a deficiency. Importantly, administration of a neutralizing anti-CD300a antibody to wild-type mice recapitulated these protective effects, promoting the shift toward SiglecF− neutrophils and significantly attenuating renal fibrosis. Together, our findings identify CD300a as a regulator of early macrophage efferocytosis and neutrophil-derived MMP9 production, and establish pharmacological CD300a blockade as a potential therapeutic strategy for progressive renal fibrosis.
- Open Access
- 6 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72261
Single‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling
Anaplastic thyroid cancer (ATC) is a rare but extremely aggressive malignancy responsible for most thyroid cancer–related deaths. To elucidate molecular and immunological characteristics distinguishing ATC from aggressive papillary thyroid cancer (PTC), we performed single‐cell RNA sequencing on three ATC and three lethal PTC samples. ATC tumor cells exhibited enhanced inflammatory and immune‐related gene expression, and co‐activation of MAPK and PI3K pathways. Notably, p53 pathway activity was suppressed in ATC, alongside activation of angiogenic and immune‐evasion programs, indicating a shift from proliferation‐driven to immune‐evasion–oriented signaling. Transcriptional network analysis revealed E2F family activation, including E2F1 , E2F7 , and E2F8 , suggesting CDK–RB–E2F axis dysregulation drives tumor dedifferentiation and proliferation, whereby p53 suppression unleashes E2F‐dependent transcriptional reprogramming. Immunoprofiling revealed CD8 + T cells in ATC showed elevated exhaustion signatures and high expression of inhibitory immune checkpoint molecules, accompanied by enhanced Treg–CD8 + T cell interactions, indicating a dual‐layered immunosuppressive mechanism involving both T‐cell exhaustion and enhanced Treg‐mediated suppression. In addition, we identified antigen‐presenting CAFs with altered CD4 + T‐cell interactions. These findings delineate a comprehensive single‐cell landscape of ATC and demonstrate coordinated alterations in tumor‐intrinsic signaling and the tumor microenvironment during dedifferentiation, provide a foundation for developing rational combination immunotherapies tailored to the molecular and immunological landscape of thyroid cancer.
- 6 September 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (9) , e72261
Open AccessSingle‐Cell Transcriptome of Anaplastic Thyroid Cancer Reveals Immunosuppressive Tumor Microenvironment Remodeling
Anaplastic thyroid cancer (ATC) is a rare but extremely aggressive malignancy responsible for most thyroid cancer–related deaths. To elucidate molecular and immunological characteristics distinguishing ATC from aggressive papillary thyroid cancer (PTC), we performed single‐cell RNA sequencing on three ATC and three lethal PTC samples. ATC tumor cells exhibited enhanced inflammatory and immune‐related gene expression, and co‐activation of MAPK and PI3K pathways. Notably, p53 pathway activity was suppressed in ATC, alongside activation of angiogenic and immune‐evasion programs, indicating a shift from proliferation‐driven to immune‐evasion–oriented signaling. Transcriptional network analysis revealed E2F family activation, including E2F1 , E2F7 , and E2F8 , suggesting CDK–RB–E2F axis dysregulation drives tumor dedifferentiation and proliferation, whereby p53 suppression unleashes E2F‐dependent transcriptional reprogramming. Immunoprofiling revealed CD8 + T cells in ATC showed elevated exhaustion signatures and high expression of inhibitory immune checkpoint molecules, accompanied by enhanced Treg–CD8 + T cell interactions, indicating a dual‐layered immunosuppressive mechanism involving both T‐cell exhaustion and enhanced Treg‐mediated suppression. In addition, we identified antigen‐presenting CAFs with altered CD4 + T‐cell interactions. These findings delineate a comprehensive single‐cell landscape of ATC and demonstrate coordinated alterations in tumor‐intrinsic signaling and the tumor microenvironment during dedifferentiation, provide a foundation for developing rational combination immunotherapies tailored to the molecular and immunological landscape of thyroid cancer.
- 20 August 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 834, 154471
CD226 associates with interferon and inflammatory programs in intestinal γδ T and group 3 innate lymphoid cells in Crohn's disease
- 20 August 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 834, 154471
CD226 associates with interferon and inflammatory programs in intestinal γδ T and group 3 innate lymphoid cells in Crohn's disease
- Open Access
Soluble CD155 immune complexes reprogram DNAM-1 signaling to potentiate antitumor immunity
Resistance to immune checkpoint inhibitors remains a major challenge in oncology, yet the mechanisms that selectively disable activating pathways are poorly defined. Here, we identify tumor-derived soluble CD155 (sCD155) as a systemic checkpoint that rewires DNAM-1 signaling to drive immunotherapy resistance. High plasma sCD155 levels correlate with impaired anti-PD-1 responses in patients with non-small cell lung cancer. Mechanistically, sCD155 selectively suppresses DNAM-1-dependent activation of CD8+ T and NK cells, uncoupling ICB from cytotoxic function. Intriguingly, a selective anti-sCD155 monoclonal antibody does not neutralize the ligand, but rather converts it into an activating scaffold. This complex induces Fc(gamma)R-anchored DNAM-1 microcluster formation and robust downstream signaling, effectively switching the checkpoint into a co-stimulatory signal. This reprogramming restores CTL function, suppresses metastasis, and augments PD-1/TIGIT blockade to achieve durable immunity. Our findings establish antibody-mediated receptor architecture rewiring as a therapeutic principle to overcome cancer immune resistance.
Open AccessSoluble CD155 immune complexes reprogram DNAM-1 signaling to potentiate antitumor immunity
Resistance to immune checkpoint inhibitors remains a major challenge in oncology, yet the mechanisms that selectively disable activating pathways are poorly defined. Here, we identify tumor-derived soluble CD155 (sCD155) as a systemic checkpoint that rewires DNAM-1 signaling to drive immunotherapy resistance. High plasma sCD155 levels correlate with impaired anti-PD-1 responses in patients with non-small cell lung cancer. Mechanistically, sCD155 selectively suppresses DNAM-1-dependent activation of CD8+ T and NK cells, uncoupling ICB from cytotoxic function. Intriguingly, a selective anti-sCD155 monoclonal antibody does not neutralize the ligand, but rather converts it into an activating scaffold. This complex induces Fc(gamma)R-anchored DNAM-1 microcluster formation and robust downstream signaling, effectively switching the checkpoint into a co-stimulatory signal. This reprogramming restores CTL function, suppresses metastasis, and augments PD-1/TIGIT blockade to achieve durable immunity. Our findings establish antibody-mediated receptor architecture rewiring as a therapeutic principle to overcome cancer immune resistance.
- Open Access
DNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation
Summary: Innate and adaptive immune responses play critical roles in the pathogenesis of inflammatory bowel disease (IBD), yet the molecular pathways integrating these responses remain elusive. Here, we identify DNAM-1 immunoreceptor as a central driver of colitis through distinct, cell type–specific mechanisms. Transcriptomic analyses of human and murine group 3 innate lymphoid cells (ILC3s) revealed DNAM-1 as a conserved IL-23–responsive surface molecule associated with inflammatory cytokine production. In an innate immune–driven anti-CD40 monoclonal antibody (mAb)–induced colitis model, DNAM-1 expressed on ILC3s promoted intestinal inflammation by enhancing IL-22 and GM-CSF production via the integration of the Akt–mTORC1–HIF-1α signaling pathway. Genetic ablation or antibody-mediated blockade of DNAM-1 attenuated inflammatory cytokine production and disease severity. Paradoxically, in T cell–dependent colitis, DNAM-1 expression on dendritic cells, but not on ILC3s or CD4⁺ T cells, exacerbated disease by promoting dendritic cell activation and pathogenic Th1 and Th17 differentiation. Notably, therapeutic blockade of DNAM-1 ameliorated disease in both colitis models and exerted complementary effects when combined with anti-TNF therapy, accompanied by modulation of immune activation programs distinct from those regulated by TNF inhibition. Collectively, these findings establish DNAM-1 as a pivotal regulator of intestinal inflammation bridging innate and adaptive immunity and identify DNAM-1 blockade as a next-generation therapeutic strategy for IBD. Highlight: ► DNAM-1 is an IL-23-responsive receptor conserved in human and mouse ILC3s. ► DNAM-1 on ILC3s drives innate colitis via Akt-mTORC1-HIF-1α signaling. ► DNAM-1 on DCs promotes T cell-dependent colitis by inducing Th1/Th17 cells. ► DNAM-1 blockade targets immune pathways distinct from TNF inhibition. ► Combined DNAM-1 and TNF blockade shows additive therapeutic efficacy in colitis.
Open AccessDNAM-1 immunoreceptor integrates innate and adaptive immune programs to drive intestinal inflammation
Summary: Innate and adaptive immune responses play critical roles in the pathogenesis of inflammatory bowel disease (IBD), yet the molecular pathways integrating these responses remain elusive. Here, we identify DNAM-1 immunoreceptor as a central driver of colitis through distinct, cell type–specific mechanisms. Transcriptomic analyses of human and murine group 3 innate lymphoid cells (ILC3s) revealed DNAM-1 as a conserved IL-23–responsive surface molecule associated with inflammatory cytokine production. In an innate immune–driven anti-CD40 monoclonal antibody (mAb)–induced colitis model, DNAM-1 expressed on ILC3s promoted intestinal inflammation by enhancing IL-22 and GM-CSF production via the integration of the Akt–mTORC1–HIF-1α signaling pathway. Genetic ablation or antibody-mediated blockade of DNAM-1 attenuated inflammatory cytokine production and disease severity. Paradoxically, in T cell–dependent colitis, DNAM-1 expression on dendritic cells, but not on ILC3s or CD4⁺ T cells, exacerbated disease by promoting dendritic cell activation and pathogenic Th1 and Th17 differentiation. Notably, therapeutic blockade of DNAM-1 ameliorated disease in both colitis models and exerted complementary effects when combined with anti-TNF therapy, accompanied by modulation of immune activation programs distinct from those regulated by TNF inhibition. Collectively, these findings establish DNAM-1 as a pivotal regulator of intestinal inflammation bridging innate and adaptive immunity and identify DNAM-1 blockade as a next-generation therapeutic strategy for IBD. Highlight: ► DNAM-1 is an IL-23-responsive receptor conserved in human and mouse ILC3s. ► DNAM-1 on ILC3s drives innate colitis via Akt-mTORC1-HIF-1α signaling. ► DNAM-1 on DCs promotes T cell-dependent colitis by inducing Th1/Th17 cells. ► DNAM-1 blockade targets immune pathways distinct from TNF inhibition. ► Combined DNAM-1 and TNF blockade shows additive therapeutic efficacy in colitis.
- 24 October 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1845-1846
A co-stimulatory signal via the coinhibitory TIGIT
- 24 October 2025
- Published by Springer Nature in Nature Immunology
- Vol. 26 (11) , 1845-1846
A co-stimulatory signal via the coinhibitory TIGIT
- Open Access
- 24 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Immunoreceptor CD300a regulates ischemic tissue damage and adverse remodeling in the mouse heart and kidney
Acute ischemic organ diseases such as acute myocardial infarction and acute kidney injury often result in irreversible tissue damage and progress to chronic heart failure (CHF) and chronic kidney disease (CKD), respectively. However, the molecular mechanisms underlying the development of CHF and CKD remain incompletely understood. Here, we show that mice deficient in CD300a, an inhibitory immunoreceptor expressed on myeloid cells, showed enhanced efferocytosis by tissue-resident macrophages and decreased damage-associated molecular patterns and pathogenic SiglecF hi neutrophils, resulting in milder inflammation-associated tissue injury than in wild-type mice after ischemia and reperfusion (IR). Notably, we uncovered that CD300a deficiency on SiglecF lo neutrophils increased the signal transducer and activator of transcription 3–mediated production of pro-angiogenic and antifibrotic factors, resulting in milder adverse remodeling after IR. Our results demonstrated that CD300a plays an important role in the pathogenesis of ischemic tissue injury and adverse remodeling in the heart and kidney.
- 24 July 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (19)
Open AccessImmunoreceptor CD300a regulates ischemic tissue damage and adverse remodeling in the mouse heart and kidney
Acute ischemic organ diseases such as acute myocardial infarction and acute kidney injury often result in irreversible tissue damage and progress to chronic heart failure (CHF) and chronic kidney disease (CKD), respectively. However, the molecular mechanisms underlying the development of CHF and CKD remain incompletely understood. Here, we show that mice deficient in CD300a, an inhibitory immunoreceptor expressed on myeloid cells, showed enhanced efferocytosis by tissue-resident macrophages and decreased damage-associated molecular patterns and pathogenic SiglecF hi neutrophils, resulting in milder inflammation-associated tissue injury than in wild-type mice after ischemia and reperfusion (IR). Notably, we uncovered that CD300a deficiency on SiglecF lo neutrophils increased the signal transducer and activator of transcription 3–mediated production of pro-angiogenic and antifibrotic factors, resulting in milder adverse remodeling after IR. Our results demonstrated that CD300a plays an important role in the pathogenesis of ischemic tissue injury and adverse remodeling in the heart and kidney.
- Open Access
- 17 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6574
Type 1 innate lymphoid cell–immature neutrophil axis suppresses acute tissue inflammation
Immature neutrophils (imNeu) are a minor population of circulating neutrophils that migrate from the bone marrow (BM) into the circulation and inflamed tissues during infection, injury, physical stress, and cancer. However, the underlying mechanism of their mobilization from BM and its pathophysiological significance remains incompletely understood. Here, we show that interferon-gamma (IFN-γ) derived from type 1 innate lymphoid cells (ILC1) enhances the migration of imNeu, but not mature neutrophils, from the BM into inflamed liver tissue with ischemia-reperfusion injury and the blood circulation during polymicrobial sepsis in mice. Mechanistically, the scaffold protein Ahnak, which is specifically expressed in imNeu, underpins Smad7 nuclear translocation in response to IFN-γ, thus downregulating C-X-C chemokine receptor 4 expression critical for neutrophil retention in the BM. Furthermore, imNeu produce interleukin-10 to ameliorate tissue inflammation. Our findings thus reveal the ILC1-imNeu axis that protects tissues from acute inflammation due to injury or microbial infection.
- 17 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 6574
Open AccessType 1 innate lymphoid cell–immature neutrophil axis suppresses acute tissue inflammation
Immature neutrophils (imNeu) are a minor population of circulating neutrophils that migrate from the bone marrow (BM) into the circulation and inflamed tissues during infection, injury, physical stress, and cancer. However, the underlying mechanism of their mobilization from BM and its pathophysiological significance remains incompletely understood. Here, we show that interferon-gamma (IFN-γ) derived from type 1 innate lymphoid cells (ILC1) enhances the migration of imNeu, but not mature neutrophils, from the BM into inflamed liver tissue with ischemia-reperfusion injury and the blood circulation during polymicrobial sepsis in mice. Mechanistically, the scaffold protein Ahnak, which is specifically expressed in imNeu, underpins Smad7 nuclear translocation in response to IFN-γ, thus downregulating C-X-C chemokine receptor 4 expression critical for neutrophil retention in the BM. Furthermore, imNeu produce interleukin-10 to ameliorate tissue inflammation. Our findings thus reveal the ILC1-imNeu axis that protects tissues from acute inflammation due to injury or microbial infection.
- Open Access
- 15 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 772, 152024
Tn antigen suppresses lipopolysaccharide-induced dermatitis via Clec10a
- 15 May 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 772, 152024
Open AccessTn antigen suppresses lipopolysaccharide-induced dermatitis via Clec10a
- Open Access
- 1 March 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (3) , 325-334
Inhibitory immunoreceptors CD300a and CD300lf cooperate to regulate mast cell activation
Mast cells (MCs) play a central role in allergic immune responses. MC activation is regulated by several inhibitory immunoreceptors. The CD300 family members CD300a and CD300lf recognize phospholipid ligands and inhibit the FcεRI-mediated activating signal in MCs. While CD300a binds to phosphatidylserine (PS) to inhibit MCs activation, CD300lf function is less clear due to its ability to bind with ceramide and PS. Moreover, it also remains blurring whether CD300a and CD300lf function independently, cooperatively, or by interfering with each other in regulating MC activation. Using imaging and flow cytometric analyses of bone marrow-derived cultured MCs (BMMCs) from wild-type (WT), Cd300a–/–, Cd300lf–/–, and Cd300a–/–Cd300lf–/– mice, we show that CD300lf and CD300a colocalized with PS externalized to the outer leaflet of the plasma membrane with a polar formation upon activation, and CD300lf cooperates with CD300a to inhibit BMMCs activation. CD300lf also colocalized with extracellular ceramide in addition to the internal PS on the cell surface, which results in stronger inhibition of MC activation than CD300lf binding to PS alone. Similarly, although both Cd300a–/– and Cd300lf–/– mice showed decreased rectal temperatures compared with WT mice in the model of passive systemic anaphylaxis, Cd300a–/–Cd300lf–/– mice showed lower rectal temperature than either Cd300a–/– or Cd300lf–/– mice. Our results demonstrate the cooperativity of multiple inhibitory receptors expressed on MCs and their regulatory functions upon binding to respective ligands.
- 1 March 2025
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 214 (3) , 325-334
Open AccessInhibitory immunoreceptors CD300a and CD300lf cooperate to regulate mast cell activation
Mast cells (MCs) play a central role in allergic immune responses. MC activation is regulated by several inhibitory immunoreceptors. The CD300 family members CD300a and CD300lf recognize phospholipid ligands and inhibit the FcεRI-mediated activating signal in MCs. While CD300a binds to phosphatidylserine (PS) to inhibit MCs activation, CD300lf function is less clear due to its ability to bind with ceramide and PS. Moreover, it also remains blurring whether CD300a and CD300lf function independently, cooperatively, or by interfering with each other in regulating MC activation. Using imaging and flow cytometric analyses of bone marrow-derived cultured MCs (BMMCs) from wild-type (WT), Cd300a–/–, Cd300lf–/–, and Cd300a–/–Cd300lf–/– mice, we show that CD300lf and CD300a colocalized with PS externalized to the outer leaflet of the plasma membrane with a polar formation upon activation, and CD300lf cooperates with CD300a to inhibit BMMCs activation. CD300lf also colocalized with extracellular ceramide in addition to the internal PS on the cell surface, which results in stronger inhibition of MC activation than CD300lf binding to PS alone. Similarly, although both Cd300a–/– and Cd300lf–/– mice showed decreased rectal temperatures compared with WT mice in the model of passive systemic anaphylaxis, Cd300a–/–Cd300lf–/– mice showed lower rectal temperature than either Cd300a–/– or Cd300lf–/– mice. Our results demonstrate the cooperativity of multiple inhibitory receptors expressed on MCs and their regulatory functions upon binding to respective ligands.